Works by Trudel, Suzanne


Results: 67
    1
    2

    Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 6, p. 484, doi. 10.1111/j.1600-0609.2011.01602.x
    By:
    • Zangari, Maurizio;
    • Aujay, Monette;
    • Fenghuang Zhan;
    • Hetherington, Kristina L.;
    • Berno, Tamara;
    • Vij, Ravi;
    • Jagannath, Sundar;
    • Siegel, David;
    • Stewart, A. Keith;
    • Wang, Luhua;
    • Orlowski, Robert Z.;
    • Belch, Andrew;
    • Jakubowiak, Andrzej;
    • Somlo, George;
    • Trudel, Suzanne;
    • Bahlis, Nizar;
    • Lonial, Sagar;
    • Singhal, Seema;
    • Kukreti, Vishal;
    • Tricot, Guido
    Publication type:
    Article
    3
    4

    Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.

    Published in:
    American Journal of Hematology, 2014, v. 89, n. 4, p. 363, doi. 10.1002/ajh.23640
    By:
    • Minden, Mark D.;
    • Hogge, Donna E.;
    • Weir, Scott J.;
    • Kasper, Jim;
    • Webster, Debra A.;
    • Patton, Lavonne;
    • Jitkova, Yulia;
    • Hurren, Rose;
    • Gronda, Marcela;
    • Goard, Carolyn A.;
    • Rajewski, Lian G.;
    • Haslam, John L.;
    • Heppert, Kathleen E.;
    • Schorno, Kevin;
    • Chang, Hong;
    • Brandwein, Joseph M.;
    • Gupta, Vikas;
    • Schuh, Andre C.;
    • Trudel, Suzanne;
    • Yee, Karen W. L.
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    P868: MEZIGDOMIDE (MEZI) PLUS DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE DOSE‐EXPANSION PHASE OF THE CC‐92480‐MM‐001 TRIAL.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970376.71405.63
    By:
    • Bahlis, Nizar J;
    • Trudel, Suzanne;
    • Quach, Hang;
    • Popat, Rakesh;
    • Lonial, Sagar;
    • Orlowski, Robert Z;
    • Kim, Kihyun;
    • Mateos, Maria‐Victoria;
    • Pawlyn, Charlotte;
    • Ramasamy, Karthik;
    • Martinez‐Lopez, Joaquín;
    • Casas‐Avilés, Ignacio;
    • Spirli, Alessia;
    • Gong, Jing;
    • Amatangelo, Michael;
    • Katz, Jessica;
    • Maciag, Paulo;
    • Peluso, Teresa;
    • Richardson, Paul
    Publication type:
    Article
    15
    16
    17
    18

    An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment – validation of official dosing guidelines.

    Published in:
    Leukemia & Lymphoma, 2020, v. 61, n. 8, p. 1860, doi. 10.1080/10428194.2020.1747064
    By:
    • Chen, Christine I.;
    • Cao, Yanshuo;
    • Trudel, Suzanne;
    • Reece, Donna E.;
    • Kukreti, Vishal;
    • Tiedemann, Rodger;
    • Prica, Anca;
    • Paul, Harminder;
    • Le, Lisa W.;
    • Levina, Olga;
    • Kakar, Sumeet;
    • Lau, Anthea;
    • Chen, Hongzhuan;
    • Chen, Eric
    Publication type:
    Article
    19
    20
    21
    22
    23
    24
    25
    26

    Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.

    Published in:
    Cancer (0008543X), 2024, v. 130, n. 15, p. 2629, doi. 10.1002/cncr.35319
    By:
    • Suvannasankha, Attaya;
    • Bahlis, Nizar;
    • Trudel, Suzanne;
    • Weisel, Katja;
    • Koenecke, Christian;
    • Oriol, Albert;
    • Voorhees, Peter M.;
    • Alonso, Aranzazu A.;
    • Callander, Natalie S.;
    • Mateos, María‐Victoria;
    • Reddy, Nishitha;
    • Hakim, Shawn;
    • LaMacchia, John;
    • Patel, Nashita;
    • Williams, Danaé;
    • Jewell, Roxanne C.;
    • Zhou, Xiangdong;
    • Gupta, Ira;
    • Opalinska, Joanna;
    • Nooka, Ajay K.
    Publication type:
    Article
    27

    Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 23, p. 3746, doi. 10.1002/cncr.34987
    By:
    • Nooka, Ajay K.;
    • Cohen, Adam D.;
    • Lee, Hans C.;
    • Badros, Ashraf;
    • Suvannasankha, Attaya;
    • Callander, Natalie;
    • Abdallah, Al‐Ola;
    • Trudel, Suzanne;
    • Chari, Ajai;
    • Libby, Edward N.;
    • Chaudhry, Maria;
    • Hultcrantz, Malin;
    • Kortüm, K. Martin;
    • Popat, Rakesh;
    • Sborov, Douglas;
    • Hakim, Shawn;
    • Lewis, Eric;
    • Gorsh, Boris;
    • Bhushan, Bharat;
    • McKeown, Astrid
    Publication type:
    Article
    28
    29
    30
    31

    Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.

    Published in:
    British Journal of Haematology, 2013, v. 162, n. 4, p. 483, doi. 10.1111/bjh.12414
    By:
    • Chen, Christine I.;
    • Masih‐Khan, Esther;
    • Jiang, Haiyan;
    • Rabea, Ahmed;
    • Cserti‐Gazdewich, Christine;
    • Jimenez‐Zepeda, Victor H.;
    • Chu, Chia‐Min;
    • Kukreti, Vishal;
    • Trudel, Suzanne;
    • Tiedemann, Rodger;
    • Tsang, Richard;
    • Reece, Donna E.
    Publication type:
    Article
    32
    33
    34

    Differential regulation of FGFR3 by PTPN1 and PTPN2.

    Published in:
    Proteomics, 2015, v. 15, n. 2/3, p. 419, doi. 10.1002/pmic.201400259
    By:
    • St‐Germain, Jonathan R.;
    • Taylor, Paul;
    • Zhang, Wen;
    • Li, Zhihua;
    • Ketela, Troy;
    • Moffat, Jason;
    • Neel, Benjamin G.;
    • Trudel, Suzanne;
    • Moran, Michael F.
    Publication type:
    Article
    35
    36
    37
    38
    39
    40

    Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study.

    Published in:
    Cancer (0008543X), 2021, v. 127, n. 22, p. 4198, doi. 10.1002/cncr.33809
    By:
    • Lonial, Sagar;
    • Lee, Hans C.;
    • Badros, Ashraf;
    • Trudel, Suzanne;
    • Nooka, Ajay K.;
    • Chari, Ajai;
    • Abdallah, Al‐Ola;
    • Callander, Natalie;
    • Sborov, Douglas;
    • Suvannasankha, Attaya;
    • Weisel, Katja;
    • Voorhees, Peter M.;
    • Womersley, Lynsey;
    • Baron, January;
    • Piontek, Trisha;
    • Lewis, Eric;
    • Opalinska, Joanna;
    • Gupta, Ira;
    • Cohen, Adam D.
    Publication type:
    Article
    41
    42
    43

    Effect of Noncompetitive Proteasome Inhibition on Bortezomib Resistance.

    Published in:
    JNCI: Journal of the National Cancer Institute, 2010, v. 102, n. 14, p. 1069, doi. 10.1093/jnci/djq198
    By:
    • Xiaoming Li;
    • Wood, Tabitha E.;
    • Sprangers, Remco;
    • Jansen, Gerrit;
    • Franke, Niels E.;
    • Xinliang Mao;
    • Xiaoming Wang;
    • Yi Zhang;
    • Verbrugge, Sue Ellen;
    • Adomat, Hans;
    • Zhi Hua Li;
    • Trudel, Suzanne;
    • Chen, Christine;
    • Religa, Tomasz L.;
    • Jamal, Nazir;
    • Messner, Hans;
    • Cloos, Jacqueline;
    • Rose, David R.;
    • Navon, Ami;
    • Guns, Emma
    Publication type:
    Article
    44

    Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2025, v. 25, n. 6, p. e404, doi. 10.1016/j.clml.2025.01.010
    By:
    • Mian, Hira S.;
    • Visram, Alissa;
    • Shih, Steven Chun-Min;
    • Trudel, Suzanne;
    • Hay, Annette E.;
    • LeBlanc, Richard;
    • Sebag, Michael;
    • Kaedbey, Rayan;
    • Stakiw, Julie;
    • Sandhu, Irwindeep;
    • Phua, Chai W.;
    • Kuruvilla, Philip G.;
    • Othman, Ibraheem;
    • Quest, Graeme;
    • McMullen, David;
    • Colasurdo, Gabriele;
    • Kotb, Rami;
    • Venner, Christopher P.
    Publication type:
    Article
    45
    46
    47

    P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S162, doi. 10.1016/S2152-2650(21)02349-1
    By:
    • Trudel, Suzanne;
    • McCurdy, Arleigh;
    • Sutherland, Heather;
    • Louzada, Martha;
    • Venner, Christopher;
    • White, Darrell;
    • Hira Mian;
    • Kotb, Rami;
    • Othman, Ibraheem;
    • Camacho, Fernando;
    • Molei Fu;
    • Engin Gul;
    • Reece, Donna
    Publication type:
    Article
    48

    P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S160, doi. 10.1016/S2152-2650(21)02346-6
    By:
    • Terpos, Evangelos;
    • Badros, Ashraf Z.;
    • Popat, Rakesh;
    • Rodríguez-Otero, Paula;
    • Farooq, Asim V.;
    • Jeng, Bennie;
    • Esposti, Simona Degli;
    • Lewis, Eric;
    • Gupta, Ira;
    • Opalinska, Joanna;
    • Palumbo, Antonio;
    • Trudel, Suzanne;
    • Jadhav, Vinay
    Publication type:
    Article
    49

    P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S156, doi. 10.1016/S2152-2650(21)02339-9
    By:
    • Richardson, Paul G.;
    • Trudel, Suzanne;
    • Callander, Natalie S.;
    • Nooka, Ajay;
    • Song, Kevin;
    • Uttervall, Katarina;
    • Minnema, Monique C.;
    • Rodríguez-Otero, Paula;
    • Struemper, Herbert;
    • Yeakey, Anne;
    • de Oca, Rocio Montes;
    • Smith, L. Mary;
    • Jackson, Nicola;
    • Kaisermann, Morrys;
    • Im, Ellie;
    • Basile, Frank G.;
    • Ahlers, Christoph M.;
    • Holkova, Beata;
    • Gupta, Ira;
    • Kremer, Brandon E.
    Publication type:
    Article
    50

    P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S139, doi. 10.1016/S2152-2650(21)02314-4
    By:
    • Ayers, Dieter;
    • Cope, Shannon;
    • Dhanda, Devender S.;
    • Towle, Kevin;
    • Mojebi, Ali;
    • Delforge, Michel;
    • Rodríguez-Otero, Paula;
    • Trudel, Suzanne;
    • Weisel, Katja;
    • Zamagni, Elena;
    • Hari, Parameswaran
    Publication type:
    Article